The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer’s disease
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-0533
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer’s disease ; day:22 ; month:9 ; year:2018 ; pages:1-14
Acta neuropathologica ; (22.9.2018), 1-14
- Creator
-
Kvartsberg, Hlin
- Contributor
-
Lashley, Tammaryn
Murray, Christina E.
Brinkmalm, Gunnar
Cullen, Nicholas C.
Höglund, Kina
Zetterberg, Henrik
Blennow, Kaj
Portelius, Erik
SpringerLink (Online service)
- DOI
-
10.1007/s00401-018-1910-3
- URN
-
urn:nbn:de:101:1-2018110620553906955617
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2024, 2:45 PM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kvartsberg, Hlin
- Lashley, Tammaryn
- Murray, Christina E.
- Brinkmalm, Gunnar
- Cullen, Nicholas C.
- Höglund, Kina
- Zetterberg, Henrik
- Blennow, Kaj
- Portelius, Erik
- SpringerLink (Online service)
Other Objects (12)
A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood
Peripheral Biomarkers for Alzheimer’s Disease: Update and Progress
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Fluid biomarkers in Alzheimer’s disease – current concepts
Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP
Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application
Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications
Levels of ADAM10 are reduced in Alzheimer’s disease CSF
Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer’s disease patients and healthy controls
Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer’s disease patients and healthy controls
A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood
Peripheral Biomarkers for Alzheimer’s Disease: Update and Progress
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Fluid biomarkers in Alzheimer’s disease – current concepts
Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP
Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application
Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications
Levels of ADAM10 are reduced in Alzheimer’s disease CSF
Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer’s disease patients and healthy controls
Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer’s disease patients and healthy controls
A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood
Peripheral Biomarkers for Alzheimer’s Disease: Update and Progress
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Fluid biomarkers in Alzheimer’s disease – current concepts
Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP
Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application
Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications
Levels of ADAM10 are reduced in Alzheimer’s disease CSF
Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer’s disease patients and healthy controls